Condition: High Grade Glioma · Anaplastic Astrocytoma · Sponsor: Ashish Shah
The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled.
This description comes directly from the study's public registry record.
Leonela Wright, MSN, RN · 305-243-0864 · lxw612@med.miami.edu
Ashish Shah, MD · 3052436946 · ashah@med.miami.edu
Always discuss trial participation with your own doctor first.
| University of Miami Hospital | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06264388